LL-37: The Antimicrobial Peptide with Broad Therapeutic Potential

The LL-37 peptide is the human body's own broad-spectrum antimicrobial peptide, part of the innate immune system that defends skin, airways and gut against bacteria, fungi and viruses. Laboratory and animal research is extensive and genuinely interesting, but human evidence for LL-37 as a treatment is limited to small, early studies, and the same molecule is implicated in some autoimmune and inflammatory skin diseases. It is not FDA-approved, and its compounding status remains under federal review.

What Is the LL-37 Peptide?

Humans make one cathelicidin protein, called hCAP-18. When it is cut by enzymes, it releases a 37-amino-acid fragment that begins with two leucines, hence the name LL-37. Neutrophils store it, and skin cells, airway lining cells and gut lining cells produce it when they sense injury or infection.

LL-37 has two broad jobs:

• Direct antimicrobial action. It is positively charged and attracted to the negatively charged membranes of microbes, where it disrupts the membrane.
• Immune signaling. It attracts immune cells, influences cytokine release, binds and neutralizes bacterial endotoxin (LPS) and participates in wound repair and new blood-vessel formation.

The Vitamin D Connection

One of the most solid findings about LL-37 has nothing to do with injections. The gene that encodes cathelicidin is switched on by the active form of vitamin D in immune and barrier cells. This is one of the mechanisms linking vitamin D status to innate immunity.

That does not mean more vitamin D is always better. It means that correcting a genuine deficiency is a reasonable, low-risk foundation step. Our article on vitamin D science vs. hype covers how to interpret levels sensibly.

LL-37 Peptide Evidence: What We Know and What We Don't

Well established (laboratory and animal):

• Mice engineered to lack cathelicidin are more susceptible to invasive skin infection, a foundational finding showing the peptide matters in host defense.
• LL-37 kills a wide range of microbes in laboratory conditions and can disrupt bacterial biofilms in vitro.
• In animal wound models, LL-37 has accelerated healing.

Early human data:

• Small early-phase clinical studies have tested topical LL-37 for hard-to-heal venous leg ulcers. Results have been mixed, and no LL-37 product has reached approval.
• Most other uses promoted online, such as chronic sinus colonization, Lyme disease, mold-related illness or "biofilm protocols," rely on lab data, extrapolation and anecdote rather than controlled trials.

Important unknowns:

• The safety of repeated injections over weeks to months.
• Whether injected LL-37 reaches infected tissue in active form, given that it is quickly broken down by enzymes.
• How it interacts with antibiotics and immunosuppressive drugs in real patients.

The Double-Edged Sword: LL-37 and Autoimmunity

This is the part of the story that is often left out. Because LL-37 amplifies immune signaling, too much of it, in the wrong place, appears to contribute to disease:

• Psoriasis. LL-37 is elevated in psoriatic skin and can bind fragments of the body's own DNA and RNA, helping trigger inflammatory immune pathways.
• Lupus. Similar complexes have been implicated in the type I interferon activity characteristic of lupus.
• Rosacea. Abnormal cathelicidin processing has been described in rosacea skin.

These are research findings, not proof that therapeutic LL-37 causes autoimmune disease. But they are a strong reason for caution in anyone with an autoimmune condition or a family history of one.

FDA Status of LL-37

LL-37 is not an FDA-approved drug for any indication.

• In 2023, FDA placed LL-37 on its 503A "Category 2" list of bulk substances raising significant safety concerns for compounding.
• On April 15, 2026, FDA removed LL-37 and eleven other peptides from Category 2 so that the Pharmacy Compounding Advisory Committee could review them. LL-37 has not yet been voted on and is expected to be reviewed before February 2027.
• Removal from Category 2 is not approval, and it does not authorize compounding. As of this writing, check current FDA guidance.

For the broader picture of where peptide rules may be heading, see the future of peptide regulation in the United States.

Who Should Be Especially Cautious

Based on its biology, a physician would want to be very careful about LL-37 in people with:

• Psoriasis, lupus, rosacea or other autoimmune disease.
• Active cancer, given its roles in cell growth and blood-vessel formation in some laboratory models.
• Pregnancy or breastfeeding, where there are no data.
• Immunosuppressive therapy, where effects are unpredictable.

How I Approach Chronic Infection and Immune Questions

Patients usually ask about LL-37 because they are frustrated: recurrent sinus infections, slow-healing wounds or a long list of symptoms attributed to infection. At Laeeq M.D., my starting point is internal medicine:

1. Confirm the diagnosis. Recurrent infections can reflect diabetes, structural sinus disease, immune deficiency, medication effects or something other than infection altogether.
2. Use appropriate testing, such as cultures, imaging or immune evaluation, before labeling a problem a "biofilm."
3. Address the foundation: blood sugar, vitamin D status, nutrition, sleep and smoking.
4. Coordinate with specialists such as infectious disease, ENT or dermatology when needed.
5. Discuss investigational peptides honestly, including their regulatory status, rather than presenting them as a shortcut.

If you are interested in other immune-related peptides, our reviews of thymosin alpha-1 and the LL-37 library entry give additional context.

Sources

• Nizet V, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature, 2001. DOI
• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA

Book a Consultation

If you are dealing with recurrent infections or wondering whether an immune-focused peptide makes sense, Dr. Laeeq can review your history and labs in a 60-minute evaluation, virtually or in person in Reston, VA. The goal is a clear diagnosis first and a safe plan second. Book a consultation to begin.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.